Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects - Trial NCT04686591
Access comprehensive clinical trial information for NCT04686591 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Completed. The study focuses on Cardiovascular Disease. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 1
Dec 21, 2020
Feb 04, 2021
Primary Outcome
Absolute bioavailability of AZD9977,The cumulative amount of AZD9977 excreted (CumAe),The cumulative amount of AZD9977 excreted and expressed as a percentage of the administered dose (CumFe),Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry,Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry,Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry
Summary
Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose
 Oral Administration
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04686591
Non-Device Trial